Compare Emerson Electric Co. (EMR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs State Street SPDR S&P Biotech ETF — how do they compare? Emerson Electric Co. trades at $161.83 (market cap $88.72B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Emerson Electric Co. is far larger — about 8.8× State Street SPDR S&P Biotech ETF's market cap, and Emerson Electric Co. pays a 1.4% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Emerson Electric Co. for 81 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| EMR | XBI | |
|---|---|---|
Market Cap | $88.72B | $10.11B |
Volume | 2,355,255 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $164.38 | $169.55 |
52-Week Low | $123.30 | $104.99 |
Typical Hold Time | 81 Days | 38 Days |
Enterprise Value | $99.80B | — |
Dividend Yield | 1.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $161.83, up 1.64% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 13.83% net income margin and a 12.81% ROE. Revenue is projected to grow to $18.6B in 2026, and the company maintains a solid balance sheet with $3.59B in cash. Analysts are largely positive, with a consensus price target of $165.90.
EMR presents a favorable outlook with upward earnings momentum and analyst support, though valuation multiples like a P/E of 34.81 suggest premium pricing. Risks include competitive pressures and macroeconomic volatility. The stock remains a candidate for growth-oriented investors seeking industrial sector exposure.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
